Revolutionizing Cancer Diagnostics through Innovation
Velsera, a key player in healthcare technology, is excited to share a major development in the field of cancer diagnostics. The company's cutting-edge tumor profiling technology is essential for the results report of the Illumina TruSight™ Oncology Comprehensive in vitro diagnostic (IVD). By combining its vast database with tumor profiling expertise, Velsera not only enhances patient care but also paves the way for more personalized treatment options nationwide.
Collaboration with Illumina
The partnership between Velsera and Illumina came together from a mutual dedication to improving cancer diagnostics and expanding access to targeted therapeutics. Since it launched in late 2018, this collaboration has become an essential alliance in the healthcare landscape. Velsera's Knowledge Base (KB) is crucial for the TSO Comprehensive test, facilitating the integration of next-generation sequencing (NGS)-based diagnostics in laboratories.
Effects on Cancer Treatment
Nicki Berry, Head of Region-Americas at Illumina, highlights how this collaboration has been vital in fulfilling the vision for the TruSight™ Oncology Comprehensive test. This NGS-based test makes it easier to identify key cancer biomarkers, which leads to improved clinical decision-making.
Improving Patient Outcomes
Velsera's Knowledge Base content is instrumental in assessing the clinical significance of cancer mutations. This advancement enables the creation of personalized and effective treatment strategies that cater to individual patient requirements. Jamie Littlejohns, the CEO of Velsera, underscores the company’s mission to make targeted therapies more accessible to healthcare providers and patients around the world. This latest achievement showcases their commitment to transforming research breakthroughs into palpable improvements in patient outcomes.
Progressing Precision Medicine
As precision medicine continues to advance, Velsera is positioned as a leader by working alongside industry giants like Illumina to innovate the diagnostics landscape. This dedication aims to fast-track the introduction of IVD solutions, setting new benchmarks for sequencing technology and ensuring quicker, more precise biomarker identification, thereby significantly enhancing patient care.
About Velsera
Founded in 2023 from the merger of Seven Bridges, PierianDx, and UgenTec, Velsera strives to be the premier platform for discovery, evidence generation, and clinical delivery in precision medicine. The company serves key regions such as Europe and Asia, assisting healthcare professionals in making informed decisions about delivering the right therapies at the right moments to the patients who need them.
Contact Information
If you have any inquiries, please reach out to:
Brian Lassiter
Manager, Commercial Marketing
Velsera
(857) 357-3060 | ext 3060
Frequently Asked Questions
What role does Velsera play in cancer diagnostics?
Velsera offers advanced tumor profiling technology that enhances the Illumina TruSight Oncology Comprehensive IVD, integrating crucial data to improve patient treatment outcomes.
How does Velsera's partnership with Illumina influence cancer treatment?
This partnership facilitates the development of an NGS-based test that simplifies the identification of significant cancer biomarkers, ultimately leading to better clinical results.
What is the significance of Velsera's Knowledge Base?
Velsera's Knowledge Base assists in categorizing cancer mutations, which in turn helps physicians devise personalized treatment plans based on the clinical importance of these mutations.
What advancements has Velsera achieved in precision medicine?
Velsera has established itself as a frontrunner in precision medicine by speeding up the development and availability of innovative diagnostic solutions specifically for cancer care.
How can I get in touch with Velsera for more details?
You can contact Brian Lassiter, the Manager of Commercial Marketing, at (857) 357-3060 for any inquiries regarding Velsera's services and products.
